Tenon Medical, Inc. Q2 2026 Earnings Call Summary

Tenon Medical, Inc.'s Q2 2026 earnings call highlighted impressive revenue growth of 127%, primarily fueled by an increase in surgical procedures and the integration of the SImmetry+ system. Gross margins expanded by 21 percentage points, reaching 64%, due to better absorption of fixed production costs and a more efficient commercial structure.

Management emphasized the importance of physician and distributor training, noting a 98% increase in events during the first half of 2026. The company's commercial strategy involves positioning Catamaran and SImmetry+ as complementary tools for various anatomical approaches. Operational efficiency improved with certain Catamaran instruments reclassified as reusable following FDA approval.

The Tampa sales and training office has exceeded expectations, driving record case values and a strong start to Q3. Management anticipates further margin expansion as revenue grows and fixed costs are absorbed. Plans include adding sales heads and partners in Q3 to support expansion. A novel posterior approach technology is nearing FDA clearance.

The company recently completed a public offering raising $4.2 million for commercial growth and debt repayment. Net loss in the first half of 2026 included $900 thousand in non-cash interest expenses related to convertible notes. Management confirmed upcoming enhancements to the SImmetry+ platform and a new decortication tool, with an FDA submission expected soon.

Despite summer seasonality, training demand is rising at the new Tampa facility, which offers an immersive environment for physicians to evaluate various technologies.